Press release
Geron to Participate at Upcoming Investor Conferences in November
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences:\n\n\n\nStifel 2023 Healthcare Conference\nTuesday, November 14th at 9:10 a.m. ET (Fireside Chat)\n\n\n\n\nPiper Sandler 35th Annual Healthcare Conference\nTuesday, November 28th at 9:30 a.m. ET (Corporate Presentation)\n\n\n\n\n\n6th Annual Evercore ISI HealthCONx Conference\nWednesday, November 29th at 10:50 a.m. ET (Fireside Chat)\n\n\n\nA webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of the Company’s website under Events. An archive of the webcast will be available on the Company’s website for 30 days.\n\n\nAbout Geron\n\n\nGeron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat for the treatment of transfusion dependent anemia in adult patients with lower risk myelodysplastic syndromes (LR MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231107595394/en/\n\nAron Feingold\nVice President, Investor Relations and Corporate Communications\n\n\nKristen Kelleher\nSenior Manager, Investor Relations\n\n\[email protected]\[email protected]\n\n\nSource: Geron Corporation","length":4693,"tagName":"div"}]